The presence of PALB2 mutations increases BC risk by 2–3 times, with carriers facing a cumulative risk of 35% within 0.6–2.7% of familial cases [64, 65].In Finland, a novel mutation (c.1592delT) led to a 4-fold increase in risk among individuals with or without a FH of the disease [63]. The gene discussed is PALB2; the disease is familial hyperaldosteronism.